Cargando…
Oncogenic KRAS signalling in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is almost universally fatal. The annual number of deaths equals the number of newly diagnosed cases, despite maximal treatment. The overall 5-year survival rate of <5% has remained stubbornly unchanged over the last 30 years, despite tremendous efforts in p...
Autores principales: | Eser, S, Schnieke, A, Schneider, G, Saur, D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150259/ https://www.ncbi.nlm.nih.gov/pubmed/24755884 http://dx.doi.org/10.1038/bjc.2014.215 |
Ejemplares similares
-
Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail
por: Elhariri, Ahmed, et al.
Publicado: (2023) -
RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer
por: Kang, R, et al.
Publicado: (2014) -
Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
por: Collins, Meredith A., et al.
Publicado: (2012) -
Mutation of the PIK3CA oncogene in human cancers
por: Karakas, B, et al.
Publicado: (2006) -
Oncogenic AKTivation of translation as a therapeutic target
por: Hsieh, A C, et al.
Publicado: (2011)